[Cross-linking and neurodermitis: prolonged re-epithelisation with severe corneal vascularisation after cross-linking in a patient with neurodermitis and keratoconus].
This case report describes a patient with keratoconus and neurodermitis suffering from a significantly prolonged postoperative time interval to re-epithelisation after corneal cross-linking. The development of corneal calcifications and vascularisations additionally inhibited proper re-epithelisation. Therefore the patient received four subsequent subconjunctival injections of Bevacizumab and an additional keratectomy to remove the calcifications. This therapeutic scheme led to a significant reduction of corneal vascularisation and finally a full rehabilitation of the epithelium.
Klinik und Poliklinik für Augenheilkunde, Universitätsklinikum Hamburg-Eppendorf, Hamburg.
I C
IC
Görsch
Klinik und Poliklinik für Augenheilkunde, Universitätsklinikum Hamburg-Eppendorf, Hamburg.
J
J
Steinberg
Klinik und Poliklinik für Augenheilkunde, Universitätsklinikum Hamburg-Eppendorf, Hamburg.
G
G
Richard
Klinik und Poliklinik für Augenheilkunde, Universitätsklinikum Hamburg-Eppendorf, Hamburg.
T
T
Katz
Klinik und Poliklinik für Augenheilkunde, Universitätsklinikum Hamburg-Eppendorf, Hamburg.
S
S
Linke
D000328:Adult; D061067:Antibodies, Monoclonal, Humanized / Q000008:administration & dosage; D000068258:Bevacizumab; D002114:Calcinosis / Q000139:chemically induced / Q000175:diagnosis / Q000503:physiopathology / Q000628:therapy; D003131:Combined Modality Therapy; D016510:Corneal Neovascularization / Q000139:chemically induced* / Q000175:diagnosis / Q000503:physiopathology* / Q000628:therapy; D003432:Cross-Linking Reagents / Q000009:adverse effects* / Q000627:therapeutic use*; D006801:Humans; D056965:Injections, Intraocular; D007640:Keratoconus / Q000175:diagnosis / Q000628:therapy*; D008297:Male; D009450:Neurodermatitis / Q000150:complications* / Q000175:diagnosis; D018903:Photorefractive Keratectomy; D011183:Postoperative Complications / Q000139:chemically induced* / Q000503:physiopathology* / Q000628:therapy; D062326:Re-Epithelialization / Q000187:drug effects* / Q000502:physiology*; D012256:Riboflavin; D066167:Slit Lamp
D061067:Antibodies, Monoclonal, Humanized; D003432:Cross-Linking Reagents; D000068258:Bevacizumab; D012256:Riboflavin